• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Biogen CEO eyes medical device market

July 23, 2018 By Sarah Faulkner

BiogenAfter taking the helm at Biogen (NSDQ:BIIB) in 2016, Michel Vounatsos made use of acquisitions and geographic expansion to grow the company. Now, Vounatsos is reportedly considering another possible opportunity to differentiate the pharmaceutical player.

The company’s chief executive hinted in an interview with Globes that Biogen could make a move into the medical technology space.

“Up until now, Biogen has focused solely on drugs. When I was appointed 18 months ago, investors asked what the next thing for us would be and how we were going to diversify the company’s products. My answer came six months later when I said that we would continue focusing on the brain because we were creating asymmetry of knowledge in this area. It was clear to every potential partner of every type – small companies, doctors, patients organizations – that we were the most prominent partner in the sector,” Vounatsos told the news outlet.

Biogen, which has made a name for itself in developing therapies for multiple sclerosis, Alzheimer’s disease and dementia, is evolving to develop treatment options for people with nerve pain, stroke and psychiatric diseases. Vounatsos predicted that the neurology space will soon see an array of therapies that combine medical devices and pharmaceuticals.

“Treatment using medication and treatment using medical devices are being combined with each other, especially in neurology. This is a movement that no one can stop. Up until now, we were more of a neuro-biological company than a neuro-technological company, but we want to expand,” he said. “Initially, we want to operate in brain imaging and advanced analysis of medical information, among other things for the sake of a better understanding of the genetics of brain development and brain activity.”

For now, the market is closing watching for data from the Phase III trials of aducanumab, a human monoclonal antibody that Biogen designed to treat Alzheimer’s disease. This degenerative brain condition has long evaded the pharmaceutical and biotech industries and Vounatsos said that the ultimate solution for patients with Alzheimer’s disease will likely involve both medical technology and drugs.

“My dream is that the pharmaceutical formulation and technology will provide a combined solution for the Alzheimer’s disease patient,” he told Globes.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS